Vera Therapeutics names new Chief Regulatory Officer
William Turner steps down from the CRO role and moves to a special advisor position, with Nancy Bowman set to replace him.
Vera Therapeutics, Inc. disclosed a leadership change in its regulatory affairs function in an 8-K dated July 9, 2026. On July 9, 2026, Vera Therapeutics, Inc. announced that William Turner will no longer serve as the Company's Chief Regulatory Officer and will transition to the role of Special Advisor for Regulatory Affairs, effective as of August 3, 2026.1
Nancy Bowman, M.D., Ph.D., will succeed Mr. Turner as the Company's Chief Regulatory Officer, effective as of August 3, 2026.1
The filing was signed by Marshall Fordyce, M.D., the company's Chief Executive Officer. The document does not provide additional biographical detail on Dr. Bowman or further explanation of the transition, and no compensatory arrangements tied to the change were disclosed in this filing.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.